158 related articles for article (PubMed ID: 26426509)
1. Mesenchymal stem cells and serelaxin synergistically abrogate established airway fibrosis in an experimental model of chronic allergic airways disease.
Royce SG; Shen M; Patel KP; Huuskes BM; Ricardo SD; Samuel CS
Stem Cell Res; 2015 Nov; 15(3):495-505. PubMed ID: 26426509
[TBL] [Abstract][Full Text] [Related]
2. Intranasally administered serelaxin abrogates airway remodelling and attenuates airway hyperresponsiveness in allergic airways disease.
Royce SG; Lim CX; Patel KP; Wang B; Samuel CS; Tang ML
Clin Exp Allergy; 2014 Nov; 44(11):1399-408. PubMed ID: 25113628
[TBL] [Abstract][Full Text] [Related]
3. Serelaxin improves the therapeutic efficacy of RXFP1-expressing human amnion epithelial cells in experimental allergic airway disease.
Royce SG; Tominaga AM; Shen M; Patel KP; Huuskes BM; Lim R; Ricardo SD; Samuel CS
Clin Sci (Lond); 2016 Dec; 130(23):2151-2165. PubMed ID: 27647937
[TBL] [Abstract][Full Text] [Related]
4. Intranasal administration of mesenchymoangioblast-derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease.
Royce SG; Rele S; Broughton BRS; Kelly K; Samuel CS
FASEB J; 2017 Sep; 31(9):4168-4178. PubMed ID: 28626025
[TBL] [Abstract][Full Text] [Related]
5. iPSC- and mesenchymoangioblast-derived mesenchymal stem cells provide greater protection against experimental chronic allergic airways disease compared with a clinically used corticosteroid.
Royce SG; Mao W; Lim R; Kelly K; Samuel CS
FASEB J; 2019 May; 33(5):6402-6411. PubMed ID: 30768365
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with relaxin and methylprednisolone augments the effects of either treatment alone in inhibiting subepithelial fibrosis in an experimental model of allergic airways disease.
Royce SG; Sedjahtera A; Samuel CS; Tang ML
Clin Sci (Lond); 2013 Jan; 124(1):41-51. PubMed ID: 22817662
[TBL] [Abstract][Full Text] [Related]
7. Relaxin plays an important role in the regulation of airway structure and function.
Samuel CS; Royce SG; Burton MD; Zhao C; Tregear GW; Tang ML
Endocrinology; 2007 Sep; 148(9):4259-66. PubMed ID: 17584966
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel model incorporating airway epithelial damage and related fibrosis to the pathogenesis of asthma.
Royce SG; Patel KP; Samuel CS
Lab Invest; 2014 Dec; 94(12):1326-39. PubMed ID: 25264707
[TBL] [Abstract][Full Text] [Related]
9. Endogenous relaxin regulates collagen deposition in an animal model of allergic airway disease.
Mookerjee I; Solly NR; Royce SG; Tregear GW; Samuel CS; Tang ML
Endocrinology; 2006 Feb; 147(2):754-61. PubMed ID: 16254028
[TBL] [Abstract][Full Text] [Related]
10. Trefoil factor-2 reverses airway remodeling changes in allergic airways disease.
Royce SG; Lim C; Muljadi RC; Samuel CS; Ververis K; Karagiannis TC; Giraud AS; Tang ML
Am J Respir Cell Mol Biol; 2013 Jan; 48(1):135-44. PubMed ID: 22652198
[TBL] [Abstract][Full Text] [Related]
11. Relaxin reverses airway remodeling and airway dysfunction in allergic airways disease.
Royce SG; Miao YR; Lee M; Samuel CS; Tregear GW; Tang ML
Endocrinology; 2009 Jun; 150(6):2692-9. PubMed ID: 19213838
[TBL] [Abstract][Full Text] [Related]
12. Suppressive effect of compact bone-derived mesenchymal stem cells on chronic airway remodeling in murine model of asthma.
Ogulur I; Gurhan G; Aksoy A; Duruksu G; Inci C; Filinte D; Kombak FE; Karaoz E; Akkoc T
Int Immunopharmacol; 2014 May; 20(1):101-9. PubMed ID: 24613203
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary myeloid cell uptake of biodegradable nanoparticles conjugated with an anti-fibrotic agent provides a novel strategy for treating chronic allergic airways disease.
Chakraborty A; Pinar AA; Lam M; Bourke JE; Royce SG; Selomulya C; Samuel CS
Biomaterials; 2021 Jun; 273():120796. PubMed ID: 33894403
[TBL] [Abstract][Full Text] [Related]
14. Serelaxin enhances the therapeutic effects of human amnion epithelial cell-derived exosomes in experimental models of lung disease.
Royce SG; Patel KP; Mao W; Zhu D; Lim R; Samuel CS
Br J Pharmacol; 2019 Jul; 176(13):2195-2208. PubMed ID: 30883698
[TBL] [Abstract][Full Text] [Related]
15. The leukotriene receptor antagonist pranlukast attenuates airway remodeling by suppressing TGF-β signaling.
Hur J; Kang JY; Rhee CK; Kim YK; Lee SY
Pulm Pharmacol Ther; 2018 Feb; 48():5-14. PubMed ID: 29031615
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta1 suppresses airway hyperresponsiveness in allergic airway disease.
Alcorn JF; Rinaldi LM; Jaffe EF; van Loon M; Bates JH; Janssen-Heininger YM; Irvin CG
Am J Respir Crit Care Med; 2007 Nov; 176(10):974-82. PubMed ID: 17761617
[TBL] [Abstract][Full Text] [Related]
17. Parabromophenacyl bromide inhibits subepithelial fibrosis by reducing TGF-β1 in a chronic mouse model of allergic asthma.
Ram A; Mabalirajan U; Jaiswal A; Rehman R; Singh VP; Ghosh B
Int Arch Allergy Immunol; 2015; 167(2):110-8. PubMed ID: 26303861
[TBL] [Abstract][Full Text] [Related]
18. Relaxin family peptide receptor-1 protects against airway fibrosis during homeostasis but not against fibrosis associated with chronic allergic airways disease.
Samuel CS; Royce SG; Chen B; Cao H; Gossen JA; Tregear GW; Tang ML
Endocrinology; 2009 Mar; 150(3):1495-502. PubMed ID: 18974264
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of mesenchymal stem cells and serelaxin effectively attenuates renal fibrosis in obstructive nephropathy.
Huuskes BM; Wise AF; Cox AJ; Lim EX; Payne NL; Kelly DJ; Samuel CS; Ricardo SD
FASEB J; 2015 Feb; 29(2):540-53. PubMed ID: 25395452
[TBL] [Abstract][Full Text] [Related]
20. Comparison of airway remodeling in acute, subacute, and chronic models of allergic airways disease.
Locke NR; Royce SG; Wainewright JS; Samuel CS; Tang ML
Am J Respir Cell Mol Biol; 2007 May; 36(5):625-32. PubMed ID: 17237192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
